322 related articles for article (PubMed ID: 21368745)
1. A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis.
Trachtman H; Fervenza FC; Gipson DS; Heering P; Jayne DR; Peters H; Rota S; Remuzzi G; Rump LC; Sellin LK; Heaton JP; Streisand JB; Hard ML; Ledbetter SR; Vincenti F
Kidney Int; 2011 Jun; 79(11):1236-43. PubMed ID: 21368745
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group.
Joy MS; Gipson DS; Powell L; MacHardy J; Jennette JC; Vento S; Pan C; Savin V; Eddy A; Fogo AB; Kopp JB; Cattran D; Trachtman H
Am J Kidney Dis; 2010 Jan; 55(1):50-60. PubMed ID: 19932542
[TBL] [Abstract][Full Text] [Related]
3. A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis.
Vincenti F; Fervenza FC; Campbell KN; Diaz M; Gesualdo L; Nelson P; Praga M; Radhakrishnan J; Sellin L; Singh A; Thornley-Brown D; Veronese FV; Accomando B; Engstrand S; Ledbetter S; Lin J; Neylan J; Tumlin J;
Kidney Int Rep; 2017 Sep; 2(5):800-810. PubMed ID: 29270487
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group.
Joy MS; Gipson DS; Dike M; Powell L; Thompson A; Vento S; Eddy A; Fogo AB; Kopp JB; Cattran D; Trachtman H
Clin J Am Soc Nephrol; 2009 Jan; 4(1):39-47. PubMed ID: 19073787
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group.
Trachtman H; Vento S; Herreshoff E; Radeva M; Gassman J; Stein DT; Savin VJ; Sharma M; Reiser J; Wei C; Somers M; Srivastava T; Gipson DS
BMC Nephrol; 2015 Jul; 16():111. PubMed ID: 26198842
[TBL] [Abstract][Full Text] [Related]
6. Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN; Alpers CE; Barratt J; Bieler S; Canetta P; Chae DW; Coppock G; Diva U; Gesualdo L; Heerspink HJL; Inrig JK; Kirsztajn GM; Kohan D; Komers R; Kooienga LA; Lieberman K; Mercer A; Noronha IL; Perkovic V; Radhakrishnan J; Rote W; Rovin B; Tesar V; Trimarchi H; Tumlin J; Wong MG; Trachtman H;
N Engl J Med; 2023 Dec; 389(26):2436-2445. PubMed ID: 37921461
[TBL] [Abstract][Full Text] [Related]
7. Proteinuria Reduction and Kidney Survival in Focal Segmental Glomerulosclerosis.
Troost JP; Trachtman H; Spino C; Kaskel FJ; Friedman A; Moxey-Mims MM; Fine RN; Gassman JJ; Kopp JB; Walsh L; Wang R; Gipson DS
Am J Kidney Dis; 2021 Feb; 77(2):216-225. PubMed ID: 32791086
[TBL] [Abstract][Full Text] [Related]
8. An Outcomes-Based Definition of Proteinuria Remission in Focal Segmental Glomerulosclerosis.
Troost JP; Trachtman H; Nachman PH; Kretzler M; Spino C; Komers R; Tuller S; Perumal K; Massengill SF; Kamil ES; Oh G; Selewski DT; Gipson P; Gipson DS
Clin J Am Soc Nephrol; 2018 Mar; 13(3):414-421. PubMed ID: 29167190
[TBL] [Abstract][Full Text] [Related]
9. Focal segmental glomerulosclerosis, excluding atypical lesion, is a predictor of renal outcome in patients with membranous nephropathy: a retrospective analysis of 716 cases.
He HG; Wu CQ; Ye K; Zeng C; Huang YY; Luo SW; Yin W; Ye QR; Peng XM
BMC Nephrol; 2019 Aug; 20(1):328. PubMed ID: 31438882
[TBL] [Abstract][Full Text] [Related]
10. Renal Survival in Patients with Collapsing Compared with Not Otherwise Specified FSGS.
Laurin LP; Gasim AM; Derebail VK; McGregor JG; Kidd JM; Hogan SL; Poulton CJ; Detwiler RK; Jennette JC; Falk RJ; Nachman PH
Clin J Am Soc Nephrol; 2016 Oct; 11(10):1752-1759. PubMed ID: 27445167
[TBL] [Abstract][Full Text] [Related]
11. DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS.
Trachtman H; Nelson P; Adler S; Campbell KN; Chaudhuri A; Derebail VK; Gambaro G; Gesualdo L; Gipson DS; Hogan J; Lieberman K; Marder B; Meyers KE; Mustafa E; Radhakrishnan J; Srivastava T; Stepanians M; Tesar V; Zhdanova O; Komers R;
J Am Soc Nephrol; 2018 Nov; 29(11):2745-2754. PubMed ID: 30361325
[TBL] [Abstract][Full Text] [Related]
12. Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis.
Fernandez-Fresnedo G; Segarra A; González E; Alexandru S; Delgado R; Ramos N; Egido J; Praga M;
Clin J Am Soc Nephrol; 2009 Aug; 4(8):1317-23. PubMed ID: 19578004
[TBL] [Abstract][Full Text] [Related]
13. Urine neutrophil gelatinase-associated lipocalin and kidney injury in children with focal segmental glomerulosclerosis.
Youssef DM; El-Shal AA
Iran J Kidney Dis; 2012 Sep; 6(5):355-60. PubMed ID: 22976261
[TBL] [Abstract][Full Text] [Related]
14. Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life.
Gipson DS; Trachtman H; Kaskel FJ; Radeva MK; Gassman J; Greene TH; Moxey-Mims MM; Hogg RJ; Watkins SL; Fine RN; Middleton JP; Vehaskari VM; Hogan SL; Vento S; Flynn PA; Powell LM; McMahan JL; Siegel N; Friedman AL
Kidney Int; 2011 Mar; 79(6):678-685. PubMed ID: 21178977
[TBL] [Abstract][Full Text] [Related]
15. Repository corticotropin injection versus corticosteroids for protection against renal damage in a focal segmental glomerulosclerosis rodent model.
Hayes K; Warner E; Bollinger C; Wright D; Fitch RM
BMC Nephrol; 2020 Jun; 21(1):226. PubMed ID: 32539845
[TBL] [Abstract][Full Text] [Related]
16. Steroid resistant focal segmental glomerulosclerosis: effect of arterial hyalinosis on outcome: single center study.
Soliman AR; Maamoun H; Soliman H; Ahmed RM
Rom J Intern Med; 2021 Jun; 59(2):127-133. PubMed ID: 33565308
[No Abstract] [Full Text] [Related]
17. Sparsentan for Focal Segmental Glomerulosclerosis in the DUET Open-Label Extension: Long-term Efficacy and Safety.
Campbell KN; Gesualdo L; Murphy E; Rheault MN; Srivastava T; Tesar V; Komers R; Trachtman H
Kidney Med; 2024 Jun; 6(6):100833. PubMed ID: 38831932
[TBL] [Abstract][Full Text] [Related]
18. Indications for kidney biopsy in idiopathic childhood nephrotic syndrome.
Alshami A; Roshan A; Catapang M; Jöbsis JJ; Kwok T; Polderman N; Sibley J; Sibley M; Mammen C; Matsell DG;
Pediatr Nephrol; 2017 Oct; 32(10):1897-1905. PubMed ID: 28540445
[TBL] [Abstract][Full Text] [Related]
19. Clinical presentation, treatment and outcome of focal segmental glomerulosclerosis in Far North Queensland Australian adults.
Greenwood AM; Gunnarsson R; Neuen BL; Oliver K; Green SJ; Baer RA
Nephrology (Carlton); 2017 Jul; 22(7):520-530. PubMed ID: 27170059
[TBL] [Abstract][Full Text] [Related]
20. Clinical Significance of IgM and C3 Glomerular Deposition in Primary Focal Segmental Glomerulosclerosis.
Zhang YM; Gu QH; Huang J; Qu Z; Wang X; Meng LQ; Wang F; Liu G; Cui Z; Zhao MH
Clin J Am Soc Nephrol; 2016 Sep; 11(9):1582-1589. PubMed ID: 27340287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
